Dr. Parveen Rewri

Associate Professor , Ophthalmology, Maharaja Agrasen Medical College, Agroha (Hisar), Haryana

1 article

A graduate from Government Medical College, Bellary & post-graduate from RNT medical College Udaipur, Parveen Rewri is committed to patient care & clinical research. He did is fellowship in clinical & research disciplines of glaucoma from Sankara Nethralya, Chennai. After working for a brief period with corporate health sector, he joined medical college. Currently, he is associate professor in Ophthalmology, and looks after glaucoma services at Maharaja Agrasen Medical College, Agroha (Hisar) in Haryana. He is fond of teaching, and actively involved in teaching of undergraduate and postgraduate students as paramedical courses of optometry and ophthalmic nursing. He is passionate about simplifying the teaching methods and contents for students. His started thinking to work in glaucoma from his postgraduation days, after he came in contact of Dr Ravi Thomas. He has chosen to work on clinical issues bothering to people he is serving or challenges being faced in day-to-day practice. He has worked on as simple as the problem to answer how long an opened bottle of eye drop can be used? Preventive ophthalmology is what he is working for now a days. In clinical research, his area of interest is angle closure glaucoma, and currently working on biochemical changes in aqueous humor in glaucoma. In his spare time, he enjoys reading Hindi and English literature, gardening and listening to classic, folk, ghazals and Sufi music. He loves to travelling and photography.

  1. Articles 4 Jun 2021 15 min read

    Trials in Glaucoma You Should Know

    Ocular Hypertension Treatment Study (OHTS) This multicentric trial recruited 1,632 patients of ocular hypertension (OHT) to answer two questions. First, if early treatment in patients of OHT with topical medication would prevent the onset of primary open-angle glaucoma (POAG). Second, which patients of OHT are more likely to develop POAG, in other words, what are the risk factors for conversion from OHT to POAG? The patients who had IOP of at least 24 mmHg in one eye and 21 mmHg in other eye, were recruited in this study. They were randomized into two groups-those who received intraocular pressure (IOP) lowering drops (Medication arm) and those who did not receive any IOP lowering drops (Observation arm). The IOP reduction was targeted at 20% in the medication group. After enrollment, patients were examined every 6-months and follow-up included a white-on-white visual field at every visit and stereoscopic disc photograph annually. The endpoint was the development of new, reproducible d

    Dr. Parveen Rewri